MADISON, Wis., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), and Onconova Therapeutics (Nasdaq:ONTX) today announced that they have entered into a strategic collaboration to develop new
NEWTOWN, Pa. , Oct. 04, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that it will host a
NEWTOWN, Pa. , Oct. 10, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), announced that they will present and
NEWTOWN, Pa. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that two abstracts relating to the Company's lead product candidate,
Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Thursday, November 9, 2017 NEWTOWN, Pa. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat
NEWTOWN, Pa. , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today provided a
NEWTOWN, Pa. , Nov. 10, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS) today announced that it
Rigosertib reduced or stabilized bone marrow blasts and improved peripheral blood counts Patients with response or stable disease had one year longer survival than non-responders Rigosertib was well tolerated and a recommended dose for further evaluation was established NEWTOWN, Pa. , Nov.
Novel formulation of rigosertib with enhanced bioavailability and stability Liver microsomal stability of ON 123300, a first-in-class dual inhibitor of CDK4/6 + ARK5 Formulation approaches to augment bioavailability of ON 123300 NEWTOWN, Pa. , Nov. 16, 2017 (GLOBE NEWSWIRE) -- Onconova
NEWTOWN, Pa. , Nov. 20, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), will present at the LD Micro